PPHETF

The State Street SPDR S&P Pharmaceuticals ETF (XPH) is reviewed as a reasonable option for investors seeking exposure to the pharmaceutical sector. With $459.89 million in assets, a low expense ratio of 0.35%, and strong year-to-date returns of 14.82%, the ETF offers diversified exposure across 64 pharmaceutical holdings.

However, it carries higher risk with a beta of 0.61 and standard deviation of 20.77%. Alternative pharmaceutical ETFs like VanEck Pharmaceutical ETF (PPH) and iShares U.S. Pharmaceuticals ETF (IHE) are also available for consideration.

The First Trust NASDAQ Pharmaceuticals ETF (FTXH) is a smart beta ETF with $1.07 billion in assets that tracks the Nasdaq US Smart Pharmaceuticals Index. With a 0.60% expense ratio and 51 holdings, it has delivered strong performance of 25.84% year-to-date and 43.75% over the past year as of October 15, 2026. However, investors should consider alternative pharmaceutical ETFs like VanEck Pharmaceutical ETF (PPH) and iShares U.S. Pharmaceuticals ETF (IHE), which offer lower expense ratios.

The article compares two healthcare ETFs: VanEck Pharmaceutical ETF (PPH) offers lower costs (0.36% expense ratio), higher dividends (1.9% yield), and a concentrated portfolio of 26 pharmaceutical companies with an established 15-year track record. Simplify Health Care ETF (PINK) provides broader healthcare exposure through active management of 58 positions with a unique charitable structure donating profits to cancer research, though it carries higher fees (0.51%) and lower yields (0.8%). For most long-term investors, PPH is recommended for its fundamentals, while PINK appeals to those seeking active management and charitable impact.

The VanEck Pharmaceutical ETF (PPH) offers low-cost exposure to the healthcare-pharma sector with a 0.36% expense ratio and $1.01 billion in assets. The fund tracks the MVIS US Listed Pharmaceutical 25 Index and holds major pharmaceutical companies like Eli Lilly, Merck, and Novartis. With a Zacks ETF Rank of 3 (Hold), year-to-date gains of 6.51%, and a medium-risk profile, PPH is presented as a reasonable option for investors seeking diversified pharma exposure, though alternative ETFs like FTXH and IHE are also available.

VanEck Pharmaceutical ETF (PPH) offers lower costs (0.36% expense ratio) and higher dividend yield (2%), making it better for long-term buy-and-hold investors. Invesco Pharmaceuticals ETF (PJP) delivered stronger 1-year returns (41% vs 31%) with more balanced U.S.-focused holdings, but charges higher fees (0.58%) and offers lower yield (0.9%).